Skip to main content
. 2011 Aug 23;105(7):1002–1011. doi: 10.1038/bjc.2011.303

Figure 7.

Figure 7

GS-168AT2 inhibits the in vivo angiogenesis and tumour growth. (A) Representative images of tumour-enriched plugs treated with either vehicle or GS-168AT2. (B) Haemoglobin contents of tumour-enriched plugs treated with either vehicle or GS-168AT2. (C) Mean tumour volume curve of mice bearing Calu-6 tumours and treated with vehicle, nonspecific protein (NCP) at 15 mg kg–1, CDDP at 5 mg kg–1, GS-168AT2 at 15.0 mg kg–1, or combined GS 168A-T2 at 15.0 mg kg–1 and CDDP at 5 mg kg–1. For both haemoglobin dosing in (B) and TV measurements on (C), results were expressed as means±s.e. of n=5, and were considered statistically significant when P-value <0.05 using two-tailed Student's t-test.